drugset / Trial / NCT03724968
Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, non-randomized two arm Phase 2 study of intravenous nivolumab plus intravenous ipilimumab or intravenous relatlimab in patients with metastatic melanoma stratified by MHC-II expression.
Timeline
- Start
- 2019-01-17
- Primary completion
- 2020-05-28
- Completion
- 2020-05-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |
| Subject | Relatlimab | Monoclonal antibody | — | Intravenous |